Monitoring for metabolic syndrome in adults with intellectual disability on atypical antipsychotic drugs

British Journal of Developmental Disabilities

Volumn 55, Issue 1, 2009, Pages 3-13

  Devapriam, John ^a   Anand, Amit ^a   Raju, Lammata Bala ^a   Bhaumik, Sabyasachi ^a  

^a Leicester Frith Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT;

ADULT; AGED; ARTICLE; AUTISM; CONTROLLED STUDY; DELUSIONAL DISORDER; FEMALE; HUMAN; INTELLECTUAL IMPAIRMENT; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICAL RECORD; MENTAL DISEASE; METABOLIC SYNDROME X; MOOD DISORDER; PATIENT MONITORING; PRACTICE GUIDELINE; RISK FACTOR; SCHIZOPHRENIA; SCHIZOTYPAL PERSONALITY DISORDER;

EID: 60349123778     PISSN: 09697950     EISSN: None     Source Type: Journal    
DOI: 10.1179/096979509799103151     Document Type: Article

References (39)

1. Alberti, K.G., Zimmet, P. and Shaw J. (2006). Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International: Diabetes Federation. Diabetic Medicine, 23, 469-480.
2. Alberti, K.G. and Zimmet, P. (1998). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation. Diabetic Medicine, 15:539-53.
3. Allison, D.B., Mentore, J.L., Heo, M., Chandler, L.P., Cappelleri, J.C. and Infante M.C. (1999). Antipsychotic-induced weight gain: a comprehensive research synthesis. American Journal of Psychiatry, 156: 1686-1696.
4. American Diabetic Association. (2004). Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care, 27, 596-601.
5. Bhaumik, S., Watson. J.M., Smith. J.F.F., Nadkarni. S, Biswas. A., Gangadharan. S.K. A lithium register for adults with intellectual disabilities - Can it work? British Journal of Developmental Disabilities, 2007, 53(1), 37-45.
6. BNF 55 (British National Formulary) March 2008. BMJ Group and Royal Pharmacological Society Publishing 2008.
7. Branford, D. (1994). A study of the prescribing for people with learning disabilities living in the community and in National Health Service care. Journal of Intellectual Disability Research, 38, 577-586.
8. Branford, D. (1996). A review of antipsychotic drugs prescribed for people with learning disabilities who live in Leicestershire. Journal of Intellectual Disability Research, 40, 358-368,
9. Brylewski, J. and Duggan, L. (2003). Antipsychotic medication for CB in PWID. Cochrane database of systematic reviews (I: 3), 1-26
10. Brown, S. (1997). Excess mortality of schizophrenia. A meta-analysis. British Journal of Psychiatry, 171, 502-508.
11. Brown, S., Birtwistle, J., Roe, L. and Thompson, C. (1999). The unhealthy lifestyle of people with schizophrenia. Psychological Medicine, 29, 697-701.
12. Clarke, DJ., Kelley, S, Thinn, K. and Corbett, J.A. (1990). Psychotropic drugs in mental retardation: I. Disabilities and the prescription of drugs for behaviour and for epilepsy in three residential settings. Journal of Mental Deficiency Research 34, 385-395.
13. Corbett, J. (1979). Psychiatric morbidity and mental retardation. In Editor Corbett J., Psychiatric Illness and Mental Handicap, 11-23 London: Royal College of Psychiatrists, Gaskell Press.
14. Deb, S. and Fraser, W. (1994). The use of psychotropic medication in people with learning disability: towards rational prescribing. Human Psychopharmacology, 9, 259-272.
15. Department of Health (2001). Valuing people: A New Strategy for Learning Disability for the 21st Century. TSO (The Stationary Office).
16. Disability Rights Commission (DRC) Report (2006). Equal Treatment: Closing the Gap. http://www.drc-gb.org/healthinvestigation
17. The IDF worldwide consensus definition of the Metabolic Syndrome (2006). International Diabetes Federation. IDF Communications, Brussels, Belgium. http://www.idf.org/home/index.cfm?node=1429
18. Joint British Societies (2005). JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 91 (supplement 5) 1-52.
19. Khan, B.U. (1997). Brief report: Risperidone for severely disturbed behaviour and tardive dyskinesia in developmentally disabled adults. Journal of Autism Developmental Disorders, 27, 479-489.
20. Lawrence, D.M., Holman, C.D.J., Jablensky, A.V. and Hobbs M.S.T (2003). Death rate from ischaemic heart disease in Western Australian psychiatric patients 1980-1998. British Journal of Psychiatry, 182, 31-36.
21. Leicestershire Partnership NHS Trust (2007). Guidance on the monitoring of metabolic parameters in patients with serious mental illness prescribed regular antipsychotics (Version March 2007) http://tinyurl.com/2anqlz
22. Linaker, O.M. (1990). Frequency of and determinants for psychotropic drug use in an institution for the mentally retarded. British Journal of Psychiatry, 156, 525-530.
23. Lund, J. (1985). The prevalence of psychiatric morbidity in mentally retarded adults. Acta Psychiatrica Scandinavica, 72, 563-570.
24. McCreadie, R.G. (2003). Diet, smoking and cardiovascular risk in people with schizophrenia. Descriptive study. British Journal of Psychiatry, 183, 534-539.
25. McGrother, C.W., Hauck, A., Bhaumik, A., Thorp, C. and Taub, N. (1996). Community care for adults with learning disability and their carers: needs and outcomes from the Leicestershire register. Journal of Intellectual Disability Research 40, 183-190.
26. Mencap (2004). Treat Me Right. Mencap.
27. Mencap (2007). Death by Indifference. Mencap.
28. Mukherjee, S., Schnur, D. B. and Reddy, R. (1989). Family history of type 2 diabetes in schizophrenic patients. Lancet, 8636, 495.
29. Newcomer, J.W. (2005). Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19, Supplement 1, 1-93.
30. Osborn, D.P., Levy, G., Nazareth, I., Petersen, I., Islam, A. and King, M.B. (2007). Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's general practice research database. Archives of General Psychiatry. 64, 242-249.
31. Phelan, M., Stradins, L. and Morrison, S. (2001). Physical health of people with severe mental illness. British Medical Journal. 322, 443-444.
32. Ryan, M.C.M, Collins, P. and Thakore, J.H. (2003). Impaired fasting glucose and elevation of cortisol in drug-naïve first-episode schizophrenia. American Journal of Psychiatry, 160, 284-289.
33. Ryan, M.C.M, Flanagan, S. and Kinsella, U. (2004). Atypical antipsychotics and visceral fat distribution in first episode, drug-naïve patients with schizophrenia. Life Sciences, 74, 1999-2008.
34. Thakore, J. H. (ed.) (2001). Physical Consequences of Depression. Cambridge, Wrightson.
35. Thakore, J.H., Vlahoos, J. and Martin, A. (2002). Increased visceral fat distribution in drug-naïve and drug-free patients with schizophrenia. International Journal of Obesity Related Metabolic Disorders, 26, 137-141.
36. Tin, N.N., Devapriam, J., Raju, L.B. and Bhaumik, S. (2008). Use of atypical antipsychotics in people with intellectual disability - is it atypical? The British Journal of Developmental Disabilities, 54, 101-111.
37. Tyrer, P., Oliver-Africano, P.C., Ahmed, Z., Bouras, N., Cooray, S., Deb, S., Murphy, D., Hare, M., Meade, M., Reece, B., Kramo, K., Bhaumik, S., Harley, D., Regan, A., Thomas, D, Rao, B., North, B., Eliahoo, J., Karatela, S., Soni, A. and Crawford, M. (2008). Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disabilities: a randomised controlled trial. Lancet, 371, 57-63
38. Welsh Office (1996). Welsh Health Survey 1995. Welsh Office.
39. Zhang, ZJ, Yao, Z.J. and Li, W. (2004). Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: magnetic resonance imaging study of previously untreated people with schizophrenia. British Journal of Psychiatry, 184, 58-62.